The DOI matches its OpenAlex record; 8 of the 8 references it cites were found in a registry or an index.
Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial
Open accessAbstract
The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999): 637]. This report assesses the efficacy of raloxifene on the long-term cumulative incidence new vertebral fractures through 4 yr. New vertebral fractures was assessed from radiographs taken at baseline, yr 2-4. The primary analysis was the cumulative incidence of new vertebral fractures through 4 yr. A posthoc analysis compared the vertebral fracture risk in yr 4 alone with that observed in the first 3 yr. The 4-yr cumulative relative risks (RR) for one or more new vertebral fractures were 0.64 [95% confidence interval (CI) 0.53, 0.76] with raloxifene 60 mg/d and 0.57 (95% CI 0.48, 0.69) with raloxifene 120 mg/d. In yr 4 alone, raloxifene 60 mg/d reduced the new vertebral fracture risk by 39% [RR 0.61 (95% CI 0.43, 0.88)], which was not found to be significantly different from the RR observed in the first 3 yr in both raloxifene groups, irrespective of prevalent fracture status. The nonvertebral fracture risk was not significantly reduced [RR 0.93 (95% CI 0.81, 1.06)]. The safety profile after 4 yr was similar to that observed after 3 yr. Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis. The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vertebral fracture assessment using a semiquantitative technique
Genant, H. K., Wu, C. Y., van Kuijk, C., & Nevitt, M. C. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650080915 · Cited by 3,691
Self-citationDelmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., Draper, M., & Christiansen, C. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712043372301 · Cited by 1,637
Self-citationMarkers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
Garnero, P., Hausherr, E., Chapuy, M.-C., Marcelli, C., Grandjean, H., Muller, C., Cormier, C., Bréart, G., Meunier, P. J., & Dr. Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111021 · Cited by 989
Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W., et al. (2001) · Breast Cancer Research and Treatment · doi:10.1023/a:1006478317173 · Cited by 678
Treatment of Established Postmenopausal Osteoporosis with Raloxifene: A Randomized Trial
Lufkin, E. G., Whitaker, M. D., Nickelsen, T., Argueta, R., Caplan, R. H., Knickerbocker, R. K., & Riggs, B. L. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.11.1747 · Cited by 237
Johnston, C. C., Bjarnason, N. H., Cohen, F. J., Shah, A., Lindsay, R., Mitlak, B. H., Huster, W., Draper, M. W., Harper, K. D., Heath, H., et al. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.22.3444 · Cited by 211
Self-citationTreatment of Postmenopausal Women with Osteoporosis or Low Bone Density with Raloxifene
Meunier, P. J., Vignot, E., Garnero, P., Confavreux, E., Paris, E., Liu-Léage, S., Sarkar, S., Liu, T., Wong, M., & Draper, M. W. (1999) · Osteoporosis International · doi:10.1007/s001980050236 · Cited by 96
Self-citation
Cited by
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Sambrook, P., & Cooper, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68891-0 · Cited by 1,165
Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women
Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A., & Wenger, N. K. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062462 · Cited by 1,048
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
From space to Earth: Advances in human physiology from 20 years of bed rest studies (1986–2006)
Pavy-Le Traon, A., Heer, M., Narici, M. V., Rittweger, J., & Vernikos, J. (2007) · European Journal of Applied Physiology · doi:10.1007/s00421-007-0474-z · Cited by 658
A comprehensive overview on osteoporosis and its risk factors
Pouresmaeili, F., Kamali Dehghan, B., Kamarehei, M., & Yong Meng, G. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s138000 · Cited by 597
Delmas, P. D., Genant, H. K., Crans, G. G., Stock, J. L., Wong, M., Siris, E., & Adachi, J. D. (2003) · Bone · doi:10.1016/s8756-3282(03)00241-2 · Cited by 545
Self-citationWatts, N. B., Bilezikian, J. P., Camacho, P. M., Greenspan, S. L., Harris, S. T., Hodgson, S. F., Kleerekoper, M., Luckey, M. M., McClung, M. R., Pollack, R. P., et al. (2010) · Endocrine Practice · doi:10.4158/ep.16.s3.1 · Cited by 441
Self-citationPowles, T. J., Ashley, S., Tidy, A., Smith, I. E., & Dowsett, M. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk050 · Cited by 430
Bone Quality: The Determinants of Bone Strength and Fragility
Fonseca, H., Moreira-Gonçalves, D., Coriolano, H.-J. A., & Duarte, J. A. (2014) · Sports Medicine · doi:10.1007/s40279-013-0100-7 · Cited by 429
de Villiers, T. J., Pines, A., Panay, N., Gambacciani, M., Archer, D. F., Baber, R. J., Davis, S. R., Gompel, A. A., Henderson, V. W., Langer, R., et al. (2013) · Climacteric · doi:10.3109/13697137.2013.795683 · Cited by 298
Stevenson, M., Lloyd Jones, M., De Nigris, E., Brewer, N., Davis, S., & Oakley, J. (2005) · Health Technology Assessment · doi:10.3310/hta9220 · Cited by 295
Ayers, C., Kansagara, D., Lazur, B., Fu, R., Kwon, A., & Harrod, C. (2023) · Annals of Internal Medicine · doi:10.7326/m22-0684 · Cited by 282
Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
Lewis-Wambi, J. S., & Jordan, V. C. (2009) · Breast Cancer Research · doi:10.1186/bcr2255 · Cited by 267
Reginster, J., Felsenberg, D., Boonen, S., Diez‐Perez, A., Rizzoli, R., Brandi, M., Spector, T. D., Brixen, K., Goemaere, S., Cormier, C., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23461 · Cited by 261
Self-citationLindsay, R., Gallagher, J. C., Kagan, R., Pickar, J. H., & Constantine, G. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.02.093 · Cited by 234
Selective estrogen receptor modulators: an update on recent clinical findings
Shelly, W., Draper, M. W., Krishnan, V., Wong, M., & Jaffe, R. B. (2008) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31816400d7 · Cited by 193
Nelson, H. D., Fu, R., Zakher, B., Pappas, M., & McDonagh, M. (2019) · JAMA · doi:10.1001/jama.2019.5780 · Cited by 137
Levy, C., Harnois, D. M., Angulo, P., Jorgensen, R., & Lindor, K. D. (2005) · Liver International · doi:10.1111/j.1478-3231.2005.01026.x · Cited by 62
Naqvi, H., Sakr, S., Presti, T., Krikun, G., Komm, B., & Taylor, H. S. (2014) · Biology of Reproduction · doi:10.1095/biolreprod.113.114165 · Cited by 54
Fracture prevention in postmenopausal osteoporosis: a review of treatment options
McCarus, D. C. (2006) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000197807.08697.06 · Cited by 24
Human serum albumin-based nanoparticles alter raloxifene administration and improve bioavailability
Yang, S.-J., Chang, C.-H., Young, T.-H., Wang, C.-H., Tseng, T.-H., & Wang, M.-L. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2111479 · Cited by 22
“Furthermore, preclinical data show that raloxifene also can display as an estrogen antagonist to reduce the risk of breast cancer incidence in postmenopausal women (Delmas et al., 2002; Waters et al., 2012).”
BackgroundThe effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease
Aleksova, J., Ebeling, P., & Elder, G. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01083-8 · Cited by 20
Combination therapy of raloxifene and alendronate for treatment of osteoporosis in elderly women
Um, M. J., Cho, E. A., & Jung, H. (2017) · Journal of Menopausal Medicine · doi:10.6118/jmm.2017.23.1.56 · Cited by 14
Metadata
- Authors
- Delmas, P. D., Ensrud, K. E., Adachi, J. D., Harper, K. D., Sarkar, S., Gennari, C., Reginster, J., Pols, H. A. P., Recker, R. R., Harris, S. T., Wu, W., Genant, H. K., Black, D. M., & Eastell, R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- Oxford University Press
- Published
- 2002-08-01
- Volume
- 87
- Issue
- 8
- Pages
- 3609-3617
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2170750104
- Cited by
- 563
- References
- 8
- FWCI
- 37.57
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.